CN108840907A - 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法 - Google Patents

酪丝亮肽-脱镁叶绿酸a单酯及其制备方法 Download PDF

Info

Publication number
CN108840907A
CN108840907A CN201810496790.5A CN201810496790A CN108840907A CN 108840907 A CN108840907 A CN 108840907A CN 201810496790 A CN201810496790 A CN 201810496790A CN 108840907 A CN108840907 A CN 108840907A
Authority
CN
China
Prior art keywords
tyroserleutide
phephorbide
carcinoma
monoesters
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810496790.5A
Other languages
English (en)
Inventor
陈志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guilin Xingda Photoelectric Medical Instrument Co Ltd
Original Assignee
Guilin Xingda Photoelectric Medical Instrument Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilin Xingda Photoelectric Medical Instrument Co Ltd filed Critical Guilin Xingda Photoelectric Medical Instrument Co Ltd
Priority to CN201810496790.5A priority Critical patent/CN108840907A/zh
Publication of CN108840907A publication Critical patent/CN108840907A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明的酪丝亮肽‑脱镁叶绿酸a单酯由酪丝亮肽与脱镁叶绿酸a发生酯化反应制备得到。酪丝亮肽作为溶于水的极性端，使得酪丝亮肽‑脱镁叶绿酸a单酯溶于水，解决了脱镁叶绿酸a水溶性差的问题，具有脱镁叶绿酸a和酪丝亮肽双重抗肿瘤作用，属于光、声动力治疗药物，可用于制备治疗皮肤病和恶性肿瘤的药物。

Description

酪丝亮肽-脱镁叶绿酸a单酯及其制备方法
技术领域
本发明涉及光、声动力治疗药物，具体是酪丝亮肽-脱镁叶绿酸a单酯。
背景技术
脱镁叶绿酸a具有一定的光敏性和热敏性，因而脱镁叶绿酸a既是一种光敏剂，也是一种很有潜力的声敏剂。它能够产生更多的ROS（活性氧簇），而且无毒、肿瘤组织高选择性及非肿瘤组织清除率高，对皮肤的副反应也较小，因此适合用于肿瘤光、声动力治疗。但是脱镁叶绿酸a水溶性差，因此限制了其在临床的开发应用。
酪丝亮肽(Tyrosyl-seryl-leucine，YSL)，是一种三肽化合物，其化学结构组成为L-酪氨酰-L-丝氨酰-L-亮氨酸，分子式为C18H27N306，分子量为381.42，易溶于冰醋酸，溶解于水。
动物实验结果显示，酪丝亮肽显示出一定的抑制肿瘤细胞生长的作用。该药在剂量为40～80μg/kg时，可使腹水型肝癌H22小鼠生命延长率达60％～90％。经四次重复实验结果稳定。在体外实验中酪丝亮肽显示出对人肝癌BEL-7402细胞增殖的抑制作用，最佳抑瘤率可达36.29％。在裸鼠移植瘤实验中，给药剂量为160～320μg/kg时，酪丝亮肽可以显著抑制人肝癌BEL-7402裸鼠移植瘤的生长，经五次重复实验，抑瘤率达40～50％。酪丝亮肽在临床实验中也显示出良好的药效，能够明显延长肝癌病人的生存时间。但在临床研究中也发现，酪丝亮肽的抗肝癌作用在不同病人的个体之间存在差异，即不同的个体对酪丝亮肽的敏感度存在差异。有些病人在给予酪丝亮肽治疗后，肿瘤生长发生了明显抑制；而有些病人在注射酪丝亮肽后肿瘤生长未受到明显影响。
未见酪丝亮肽与脱镁叶绿酸a结合的报道。
发明内容
为了综合酪丝亮肽与脱镁叶绿酸a的优点，克服各自的缺点，开发更好的用于光、声动力治疗的药物，本发明提供酪丝亮肽-脱镁叶绿酸a单酯。
酪丝亮肽-脱镁叶绿酸a单酯的结构如下式：
由酪丝亮肽与脱镁叶绿酸a发生酯化反应制备得到。
酪丝亮肽-脱镁叶绿酸a单酯的制备方法，包括下述步骤：
1）、在保护气体和避光条件下，酪丝亮肽与脱镁叶绿酸a发生酯化；
2）、离心，上清液以去离子水透析，冷冻干燥。
3）、干燥物用硅胶柱层析分离，洗脱剂是体积比为3/7~7/3的二氯甲烷/甲醇的混合溶液；
4）、挥去二氯甲烷/甲醇后，用甲醇或乙腈溶解，用反相柱层析精制纯化，洗脱剂为甲醇/水混合液或乙腈/水混合液；所述反相柱使用的填料为C18；所述甲醇/水混合液或乙腈/水混合液的体积比为3/7~7/3；
5）、所得纯化液浓缩至干，再将浓缩物真空干燥24~36h或冷冻干燥，得目标产物。
酪丝亮肽-脱镁叶绿酸a单酯的应用，在于制备治疗皮肤病和恶性肿瘤的药物，所述皮肤病包括：尖锐湿疣、扁平疣、痤疮、鲜红斑痣、毛细血管瘤，所述恶性肿瘤包括：食管癌、肺癌、脑瘤、头颈部肿瘤、眼肿瘤、咽癌、胸壁肿瘤、乳腺癌、胸膜间皮瘤、腹腔肉瘤、膀胱癌、妇科肿瘤、直肠癌、Kaposi肉瘤、皮肤癌、口腔癌、喉癌、宫颈癌、阴道癌、外阴癌、阴茎癌、肝癌、胆管癌、白血病。
本发明的酪丝亮肽-脱镁叶绿酸a单酯具有下述主要的优点：
1）、酪丝亮肽作为溶于水的极性端，使得酪丝亮肽-脱镁叶绿酸a单酯溶于水，解决了脱镁叶绿酸a水溶性差的问题。
2）、具有脱镁叶绿酸a和酪丝亮肽双重抗肿瘤作用，通过效果互补解决了酪丝亮肽的抗肝癌作用在不同病人的个体之间存在差异的问题。
附图说明
图1是实施例1目标产物的H1-NMR图。
图2是实施例1目标产物的C13-NMR图。
具体实施方式
实施例1
在保护气体和避光条件下，脱镁叶绿酸a溶于乙醇中，为A。酪丝亮肽溶于冰醋酸后，加入A，40℃条件搅拌下下反应48h；其中脱镁叶绿酸a与酪丝亮肽为等摩尔量。
离心，上清液以去离子水透析，冷冻干燥。
干燥物用硅胶柱层析分离，洗脱剂是体积比为3/7~7/3的二氯甲烷/甲醇的混合溶液；
挥去二氯甲烷/甲醇后，用甲醇或乙腈溶解，用反相柱层析精制纯化，洗脱剂为甲醇/水混合液或乙腈/水混合液；所述反相柱使用的填料为C18；所述甲醇/水混合液或乙腈/水混合液的体积比为3/7~7/3；
所得纯化液浓缩至干，再将浓缩物真空干燥24~36h或冷冻干燥，得目标产物酪丝亮肽-脱镁叶绿酸a单酯。
纯度达到HPLC大于95%，产率大于67％。
酪丝亮肽-脱镁叶绿酸a单酯的H1-NMR、C13-NMR如图1、2。分析可知结构得到确证。
酪丝亮肽-脱镁叶绿酸a单酯在50 mmol/L pH4.0的醋酸盐缓冲液中的溶解度最大为14.2mg/ml，在pH5.0～7.5范围内溶解度为10.6mg/ml。
应用例1
体外抗癌活性评价：
光动力活性：BEL-7402肝癌细胞，663nm的吸收波长，光源高度为20cm，抑瘤率可达53.25％。
声动力活性：BEL-7402肝癌细胞，距超声发声探头2cm，超声激发(2MHz，2W)2min，抑瘤率可达42.97％。

Claims (3)

1.如下式的酪丝亮肽-脱镁叶绿酸a单酯：
由酪丝亮肽与脱镁叶绿酸a发生酯化反应制备得到。
2.权利要求1所述的酪丝亮肽-脱镁叶绿酸a单酯的制备方法，包括下述步骤：
1）、在保护气体和避光条件下，酪丝亮肽与脱镁叶绿酸a发生酯化；
2）、离心，上清液以去离子水透析，冷冻干燥；
3）、干燥物用硅胶柱层析分离，洗脱剂是体积比为3/7～7/3的二氯甲烷/甲醇的混合溶液；
4）、挥去二氯甲烷/甲醇后，用甲醇或乙腈溶解，用反相柱层析精制纯化，洗脱剂为甲醇/水混合液或乙腈/水混合液；所述反相柱使用的填料为C18；所述甲醇/水混合液或乙腈/水混合液的体积比为3/7～7/3；
5）、所得纯化液浓缩至干，再将浓缩物真空干燥24～36h或冷冻干燥，得目标产物。
3.权利要求1所述的酪丝亮肽-脱镁叶绿酸a单酯的应用，在于制备治疗皮肤病和恶性肿瘤的药物，所述皮肤病包括：尖锐湿疣、扁平疣、痤疮、鲜红斑痣、毛细血管瘤，所述恶性肿瘤包括：食管癌、肺癌、脑瘤、头颈部肿瘤、眼肿瘤、咽癌、胸壁肿瘤、乳腺癌、胸膜间皮瘤、腹腔肉瘤、膀胱癌、妇科肿瘤、直肠癌、Kaposi肉瘤、皮肤癌、口腔癌、喉癌、宫颈癌、阴道癌、外阴癌、阴茎癌、肝癌、胆管癌、白血病。
CN201810496790.5A 2018-05-22 2018-05-22 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法 Withdrawn CN108840907A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810496790.5A CN108840907A (zh) 2018-05-22 2018-05-22 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810496790.5A CN108840907A (zh) 2018-05-22 2018-05-22 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法

Publications (1)

Publication Number Publication Date
CN108840907A true CN108840907A (zh) 2018-11-20

Family

ID=64213219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810496790.5A Withdrawn CN108840907A (zh) 2018-05-22 2018-05-22 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法

Country Status (1)

Country Link
CN (1) CN108840907A (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980886A (zh) * 2014-05-28 2014-08-13 国家纳米科学中心 一种荧光分子探针及其制备方法和应用
CN104086554A (zh) * 2014-05-30 2014-10-08 桂林晖昂生化药业有限责任公司 一种新型的完全水溶的光敏剂单体及其制备方法及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980886A (zh) * 2014-05-28 2014-08-13 国家纳米科学中心 一种荧光分子探针及其制备方法和应用
CN104086554A (zh) * 2014-05-30 2014-10-08 桂林晖昂生化药业有限责任公司 一种新型的完全水溶的光敏剂单体及其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WOORAM PARK等: "A highly tumor-specific light-triggerable drug carrier responds to hypoxic tumor conditions for effective tumor treatment", 《BIOMATERIALS》 *
简序等: "酪丝亮肽荧光标记物的合成及其在肿瘤治疗靶点研究中的应用 ", 《生物化学与生物物理进展》 *

Similar Documents

Publication Publication Date Title
CN108619511B (zh) 一种基于阿糖胞苷小分子前药的金属有机框架载药系统的制备方法和应用
US11752210B2 (en) Sensitizing composition using electromagnetic waves for thermal therapy of cancers, and cancer therapy using same
CN108707183A (zh) 酪丝亮肽-二氢卟吩e6单酯及其制备方法
WO2018028511A9 (zh) 杨梅素衍生物及制备方法，及其在治疗结肠炎、防治结肠炎癌转化和治疗结直肠癌中的应用
CN104387389A (zh) 1,2,3-三唑-黄酮类化合物-苦参碱三元轭联物和用途
CN113336768B (zh) 一种多靶点酪氨酸激酶抑制剂
JP6462147B2 (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
CN108836937A (zh) 顺铂纳米药物制剂、制备方法和应用
CN108840907A (zh) 酪丝亮肽-脱镁叶绿酸a单酯及其制备方法
CN108771759A (zh) 酪丝亮肽-二氢卟吩e6金属络合物酯及其制备方法
WO2010081266A1 (zh) 延胡索乙素的新用途
CN114456152B (zh) 一种高尔基体靶向的共价结合蛋白的光热试剂及其制备方法和应用
CN108641009A (zh) 二氢卟吩e6-香菇多糖酯及其制备方法
CN113018276B (zh) 一种增强声动力治疗的肺癌靶向自组装纳米药物及其制备与应用
RU2345086C2 (ru) Способ получения цис-диаммонийдихлордигидроксоплатины (iv) и ее применение
CN114605475A (zh) 轴向含有3-溴丙酮酸配体的口服Pt(Ⅳ)抗癌前药
CN108383923A (zh) 脱镁叶绿酸a-香菇多糖酯及其制备方法
CN108659140A (zh) 二氢卟吩e6金属络合物-香菇多糖酯及其制备方法
CN106366088A (zh) 小白菊内酯衍生物，其药物组合物及其制备方法和用途
WO2008154801A1 (fr) Dérivé d'acide trans-cinnamique, son procédé de préparation et son utilisation
CN111763185A (zh) 侧链环氧化的前列腺素衍生物及其组合物与用途
RU2695380C1 (ru) Полиацилированные производные 20(r)-гинзенозида rg3, их получение и применение
CN115626946B (zh) 一种桦木醇-卡洛芬衍生物及其自组装纳米颗粒和在制备抗肺癌药物中的用途
CN105477068B (zh) 一种桑枝叶活性部位的制备方法及其应用
CN114409669B (zh) 一种氧杂降冰片烯环上c-5位炔基取代的斑蝥素衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20181120